Supplementary Table 1. Primers used for sequencing the *MARCO* gene.

Fragment	Region	Forward	Reverse
1	Exon 1	AAAGCCTCCTCGATCC	GCAATAAGCCAAACCTAGAC
2	Exon 2	AGCCACACAGATGAGTGACC	CTCAGGCACACATACACA
3	Exon 3	GAATGTCAGGGATATGCTCA	GGTTCAGACTTGGCATTG
4	Exon 4	TGCAGTCCGCTAGTTG	ACAGGGGAAGGTAAGCTA
5	Exons 5 and 6	TTGCCCCATCCTGTTGACTG	CTTCCCAGCCTCTCATCCCC
6	Exon 7	GGAGAAATGGAACTAGCTCT	GCATCATTTGTCCCTAGCAG
7	Exon 8	CCCTTCTCTCCCAAATGCTT	TCTCTTTGCTCACCCGGAA
8	Exons 9 and 10	GCGGTCATATCTTCCACTCG	ACTGGCTGCTCTGTTCCTC
9	Exons 11 and 12	GGTGTTAAAGCTGCCAAGAG	CAAGGCACAGAAGACCCTC
10	Exon 13	CCAATGTATCTTTCCATCTGC	AAATCTGAGGCTTGAGTGAC
11	Exon 14	ATTTTAGCCTGCCTGTTCTCG	AAGCCCCAGCACAAGACT
12	Exon 15	CCAATCTAACTTCAACCCCTC	ATTTTCAGGTGCAGAATTGACT
13	Exon 16	CCAAAATGAAAAGAAAGAGCCC	CTGGATGGACCTTGACCGAA
14	Exon 17	AGTGAGAAGTCGGCAGTCCA	TCACCACCTCCAACCTC

Supplementary Table 2. Primers and probes for genotyping assays.

Variation	Method	Forward primer	Reverse primer	VIC-probe	FAM-probe
H101Q	TaqMan	CCCGTCCTTCTCCTTGCT	CAGGACTTGCAGCCTCGAT	TTCTCCAGGGTGTGCTG	TCTCCAGGCTGTGCTG
K201N	TaqMan	CTCGGGACCCCAAGGC	GGTACATACCCAGCACCTACTCA	CCGCCTCTCCCTTGACT	CGCCTCTCCGTTGACT
F282S	TaqMan	AAGACTTTTTGGTTTTTCAGGAAGCAA	CCACGTGCCCTCTTACCT	CCTCCCGAAGTCACC	CTCCCGGAGTCACC
P303L	TaqMan	CACAGCCTGGCAGTCACT	GGAGGGCCCGGAACAC	CAGTCCAGGTTGTCC	CAGTCCAAGTTGTCC
G319V	TaqMan	CCCTCCTGGTGCAGTGG	GGACCCAGGACCTCACCT	ACACCCAGGTGCCAAG	ACACCCAGTTGCCAAG
K387Q	TaqMan	GCAGGTGTGAAGGGAGAACAG	CCCTTCTGGCCAGCTTGTC	CAGGTCCCAAGGGAG	CAGGTCCCCAGGGAG
E511D	TaqMan	TGGAGCTGCACCAAGAATAGC	GAAAGGGTTTCCGGGTCAGA	CTGCGTCCTCCTCGTG	CTGCGTCCTCGTCGTG

Supplementary Table 3. Characteristics of participants with extreme lung phenotypes in the Copenhagen City Heart Study

	Without extreme lung phenotype	Asthma	COPD	Interstitial lung disease	High FEV_1	Low FEV_1 smokers	Low FEV_1 nonsmokers
Number	9844	174	175	31	140	122	118
Age, yrs	59 (45-70)	44 (35-53)	61 (56-66)	68 (60-74)	55 (43-66)	59 (44-68)	58 (42-68)
Female, %	56	64	51	61	55	57	54
FEV_1, % of predicted value	94 (83-105)	89 (78-97)	65 (50-80)	64 (43-92)	133 (124-141)	40 (31-58)	52 (36-67)
FEV_1/FVC	0.79 (0.74-0.83)	0.79 (0.73-0.83)	0.67 (0.57-0.75)	0.70 (0.57-0.81)	0.82 (0.80-0.87)	0.54 (0.45-0.69)	0.63 (0.50-0.78)
Current smokers, %	47	14	83	52	29	100	0
Ex-smokers, %	29	44	15	42	33	0	83
Packyears	15 (0-35)	2 (0-15)	40 (26-53)	33 (23-48)	2 (0-17)	34 (20-44)	16 (0-38)

Values represent median (interquartile range) or percentages. Asthma=affirmative to the question “Do you have asthma?”. COPD=chronic obstructive pulmonary disease was FEV_1/FVC<0.7 and FEV_1% predicted<80%. Interstitial lung disease=ICD8:517, ICD10:J84. High FEV_1=the 140 individuals who had the highest FEV_1%predicted. Low FEV_1 smokers=the 122 individuals with the lowest FEV_1%predicted among current smokers. Low FEV_1 nonsmokers=the 118 individuals with the lowest FEV_1%predicted among exsmokers and nonsmokers.



Supplementary figure 1

Figure legends

Supplementary figure 1 - Risk of self-reported asthma and self-reported use of asthma medication according to macrophage receptor with collagenous structure (*MARCO*) genotype. Values represent odds ratios and 95% confidence intervals. Logistic regression models allowed for age, sex, and packyears.